White Papers
This is the first in a series of white papers by the experts at PharmaVentures that explores the challenges of valuing drug candidates at various stages of clinical development. This series is based on the experiences we have encountered using valuation in actual negotiations with the various pitfalls that negotiators and valuation practitioners have while negotiating a deal.
White Papers
In the recent years, the level of interest in Gene Therapy from both industry and academia has been unparalleled. CNS disorders in particular have gained a lot of attention with a considerable emphasis on neurological targets; and this is especially visible when analysing several high-profile deals that occurred in 2018. The biggest stand-out deal was struck by Novartis, buying AveXis for $8.7 billion giving the Basel based biopharma company access to what could potentially be the first one-time only treatment for Spinal Muscular Atrophy (SMA). On top of this, AveXis will also give Novartis access to a promising platform technology based around a non-replicating adeno-associated virus (AAV) capsid that allows penetratration of the blood brain barrier.
White Papers
Barely a month passes without an announcement of improved survival rates for non-small cell lung cancer (NSCLC) patients. Much of this has been driven by favouring a personalised medicine approach over the historic “one size fits all” chemotherapy paradigm. Drugs which target specific mutations such as EGFR and ALK have been at the forefront and this has been further supplemented with the application of anti-PD-1/PD-L1 agents (as monotherapies or in combination) where Merck’s Keytruda® (Pembrolizumab) has been leading the charge. In fact, ASCO 2018 has solidified Merck’s dominant position in first line settings.
White Papers
Despite the impressive growth observed in China over the last two decades and with a projected healthcare market of RMB 8 trillion (USD 1.2 trillion), Chinese life science companies lag behind toptiered Western counterparts, both in terms of market capitalisation and innovation. What makes 2017 remarkable is that the age of pure window shopping by Chinese players seems to be something of the past and companies are actively pursuing international strategies. Ambitious and visionary pharmaceutical companies and healthcare investors are all establishing their footprints across the world. The next five years point to exponential growth in crossborder knowledge and capital exchange, offering unprecedented opportunities for deal making between the West and the East for those who are prepared. This article highlights some of the changes, opportunities and challenges. We believe that three key themes will dominate this coming period: industry consolidation, technological innovation and optimisation of capital operation and deployment.
White Papers
On May 26th 2017, a new set of European Medical Device Regulations (“MDR”) and In Vitro Diagnostic Regulations (“IVDR”) entered into force. They represent a major overhaul and tightening of the previous directives and affect all companies marketing or developing devices and/or diagnostics under their name or trademark in the EU (termed ‘manufacturers’ in the regulations). The changes introduce a standardised regulatory framework for the EU that aims to be robust, transparent, and to overcome differences in interpretation and weaknesses brought to light in recent safety scandals.
White Papers
Today the top ten best-selling antibody therapeutics for cancer have accumulated revenues approaching $200 Billion, the bulk of which is accounted for by sales of the four leading agents.
